Investor

The rounds this investor is named on, who it invests beside, and where it shows up.

NYBC Ventures: 1 round · Fireround

AvenCell Therapeutics[ PART ]

A privately held clinical-stage company developing CAR-T therapies

Series B$112M2024-10-221 [ HISTORY ]

Company	Round	Amount	Announced	Role
AvenCell Therapeutics A privately held clinical-stage company developing CAR-T therapies	Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$112M	2024-10-22	[ PART ]